Receptor-mediated mechanisms of peroxisome proliferators

Biochemical Pharmacology

Volumn 43, Issue 3, 1992, Pages 393-401

  Green, Stephen ^a  

^a AKZO NOBEL CENTRAL RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CLOFIBRIC ACID; HORMONE RECEPTOR; METHYLCLOFENAPATE; NAFENOPIN; PEROXISOME PROLIFERATOR; PHTHALIC ACID 2 ETHYLHEXYL MONOESTER; PIRINIXIC ACID; TRICHLOROACETIC ACID;

CARDIOVASCULAR DISEASE; DRUG MECHANISM; HUMAN; LIPID METABOLISM; LIVER CARCINOGENESIS; NONHUMAN; PEROXISOME; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE;

ANIMAL; ANTILIPEMIC AGENTS; CARCINOGENS; CARRIER PROTEINS; CELL NUCLEUS; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; HUMAN; MICROBODIES; RECEPTORS, CELL SURFACE; TRANS-ACTIVATORS;

EID: 0026529169     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(92)90554-V     Document Type: Article

References (101)

1. Drugs and lipid metabolism
2. Therapeutic significance of hypolipidemic and antiatherosclerotic drugs
3. Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate
4. Tumorigenicity of the hypolipidaemic peroxisome proliferator ethyl-α-p-chlorophenoxyisobutyrate (clofibrate) in rats
5. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens
6. Regulation of the mevalonate pathway
7. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs
8. Comparative clinical therapeutic trial with two hypolipidemic drugs: clofibrate and nafenopin
9. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up
10. The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study
11. Simvastatin versus gemfibrozil in the treatment of primary hyperchole-sterolemia in hypertensive patients treated with hydrochlorothiazide
12. Role of the endocrine system in the regulation of plasma lipids and fibrinogen, with particular reference to the effects of ‘Atromid’-S
13. Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxyisobutyrate
14. Plasma lipoproteins and regulation of hepatic metabolism of fatty acids in altered thyroid states
15. Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia
16. Effects of chlorophenoxyisobutyrate on the synthesis and metabolism of cholesterol in man
17. Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans
18. Biochemical mechanisms of induction of hepatic peroxisome proliferaton
19. Peroxisome proliferation and nongenotoxic carcinogenesis Commentary on a symposium
20. Nature of the hepatomegalic effect produced by ethyl-chlorophenoxyisobutyrate in the rat
21. Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy 14,643), in rat and mouse liver
22. A species comparison of acute hyperplasia induced by the peroxisome proliferator methylclofenapate: Involvement of the binucleated hepatocyte
23. A fatty acyl-CoA oxidizing system in rat liver peroxisomes; Enhancement by clofibrate, a hypolipidemic drug
24. On the mechanism of induction of the enzyme systems for peroxisomal β-oxidation of fatty acids in rat liver by diets rich in partially hydrogenated fish oil
25. The effect of high-fat diets on microsomal lauric acid hydroxylation in rat liver
26. Peroxisome proliferation and induction of peroxisomal enzymes in mouse and rat liver by dehydroepiandrosterone feeding
27. Enhancement of fatty acyl-CoA oxidizing activity in rat liver peroxisomes by di-(2-ethylhexyl)phthalate
28. Differential increase of hepatic peroxisomal, mitochondrial and microsomal carnitine acyltransferases in clofibrate-fed rats
29. The effect of hypolipidemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat. Induction of cytochrome(s) P-450 with specificity toward terminal hydroxylation of lauric acid
30. Cytochrome P-450 induction by clofibrate. Purification and properties of a hepatic cytochrome P-450 relatively specific for the 12-and 11-hydroxylation of dodecanoic acid (lauric acid)
31. 2α
32. Transcriptional regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators
33. Structural analysis of cDNA for rat peroxisomal 3-ketoacyl-CoA thiolase
34. Isolation, complementary DNA sequence, and regulation of rat hepatic lauric acid ω-hydroxylase (cytochrome P-450LAω). Identification of a new cytochrome P-450 gene family
35. The rat clofibrate-inducible CYP4A subfamily II. cDNA sequence of IVA3, mapping of the Cyp4a locus to mouse chromosome 4, and coordinate and tissuespecific regulation of the CYP4A genes
36. Differential induction of peroxisomal and microsomal fatty-acid-oxidising enzymes by peroxisome proliferators in rat liver and kidney. Characterisation of a renal cytochrome P-450 and implications for peroxisome proliferation
37. Thyromimetic effect of peroxisomal proliferators in rat liver
38. 3H]thymidine and Salmonella mutagenesis assays
39. Sequential histologic study of rat liver during peroxisome proliferator [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643)-induced carcinogenesis
40. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl) phthalate and [4-chloro - 6 - (2,3-xylidino) - 2 -pyrimidinylthio]acetic acid (Wy 14,643) in rats
41. The carcinogenicity of dietary di(2-ethylhexyl) phthalate (DEHP) in Fischer 344 rats and B6C3F1 mice
42. Formation of 8-hydroxydeoxyguanosine in liver DNA of rats following long-term exposure to a peroxisome proliferator
43. 32P-postlabeling
44. Relationship of oxidative damage to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and Wy-14, 643.
45. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate a peroxisome proliferator
46. Differences between the promoting activities of the peroxisome proliferator WY-14,643 and phenobarbital in rat liver
47. Failure of the peroxisome proliferator WY-14,643 to initiate growth-selectable foci in rat liver
48. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
49. Peroxisome proliferators and cancer: Mechanisms and implications.
50. Detection of a nafenopin-binding protein in rat liver cytosol associated with the induction of peroxisome proliferation by hypolipidemic compounds
51. Peroxisome proliferator-binding protein: Identification and partial characterization of nafenopin-, clofibric acid-, and ciprofibrate-binding proteins from rat liver
52. Identification of cytosolic peroxisome proliferator binding protein as a member of the heat shock protein HSP70 family
53. Nuclear receptors enhance our understanding of transcription regulation
54. The steroid and thyroid hormone receptor superfamily
55. Steroid receptor family: Structure and functions
56. Characterization of DNA sequences through which cadmium and glucocorticoid hormones induce human metallothionein-IIA gene
57. The estrogen-responsive element as an inducible enhancer: DNA sequence requirements and conversion to a glucocorticoid-responsive element
58. Negative regulation by glucocorticoids through interference with a cAMP responsive enhancer
59. Glucocorticoid repression of pro-opiomelanocortin gene transcription
60. The thyroid hormone receptor binds with opposite transcriptional effects to a common sequence motif in thyroid hormone and estrogen response elements
61. Positive and negative regulation of gene transcription by a retinoic acid-thyroid hormone receptor heterodimer
62. Zinc fingers: A novel protein fold for nucleic acid recognition
63. Solution structure of the DNA-binding domain of the oestrogen receptor
64. Three amino acids of the oestrogen receptor are essential to its ability to distinguish an oestrogen from a glucocorticoid-responsive element
65. Determinants of target gene specificity for steroid/thyroid hormone receptors
66. Two amino acids within the knuckle of the first zinc finger specify DNA response element activation by the glucocorticoid receptor
67. Localisation of the oestradiol-binding and putative DNA-binding domains of the human oestrogen receptor
68. Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor
69. Mapping the HSP90 binding region of the glucocorticoid receptor
70. Several regions of human estrogen receptor are involved in the formation of receptorheat shock protein 90 complexes
71. Comparison of constitutive and inducible levels of expression of peroxisomal β-oxidation and catalase genes in liver and extrahepatic tissues of rat
72. Peroxisome proliferation due to di(2-ethylhexyl) phthalate (DEHP): Species differences and possible mechanisms
73. The effect of hypolipidaemic agents on peroxisomal β-oxidation and mixed-function oxidase activities in primary cultures of rat hepatocytes. Relationship between induction of palmitoyl-CoA oxidation and lauric acid hydroxylation
74. Structure-activity relationships for hepatic peroxisome proliferation
75. Induction of peroxisomal β-oxidation in the rat liver in vivo and in vitro by tetrazole-substituted acetophenones: Structure-activity relationships
76. In vitro formation of bile acids from di-and trihydroxy-5β-cholestanoic acid in human liver peroxisomes
77. Dehydroepiandrosterone and structural analogs: A new class of cancer chemopreventive agents
78. Inhibition of 3α, 7α, 12α-trihydroxy-5β-cholestanoic acid oxidation and of bile acid secretion in rat liver by fatty acids
79. Identification of a retinoic acid responsive element in the retinoic acid receptor β gene
80. The late retinoic acid induction of laminin B1 gene transcription involves RAR binding to the responsive element
81. Isolation and structural characterization of the rat acyl-CoA oxidase gene
82. Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of the rat acyl-CoA oxidase gene
83. Clofibrate enhancement of mitochondrial carnitine transport system of rat liver and augmentation of liver carnitine and γ-butyrobetaine hydroxylase activity by thyroxine
84. Factors influencing peroxisome proliferation in cultured rat hepatocytes
85. Time course of peroxisome biogenesis during adaptation to mild hyperthyroidism in rat liver: A morphometric/stereologic study by electron microscopy
86. Effects of phthalic acid esters on the liver and thyroid
87. Spatial distribution of cellular protein binding to retinoic acid in the chick limb bud
88. Timmermann-Troiener I and Schulte-Hermann R, Effects of hypolipidemic drugs nafenopin and clofibrate on phenotypic expression and cell death (apoptosis) in altered foci of rat liver
89. Mechanisms of tumor induction by peroxisome proliferators
90. Differential proto-oncogene mRNA induction from rats treated with peroxisome proliferators
91. Suppression of EGF binding in rat liver by the hypolipidemic peroxisome proliferators, 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio (N-β-hydroxyethyl) acetamide and di(2-ethylhexyl)phthalate
92. Quantitative microscopy comparison of peroxisome proliferation by the lipid-regulating agent gemfibrozil in several species
93. Clobuzarit: Species differences in the morphological and biochemical response of the liver following chronic administration
94. Species differences in carcinogenicity and peroxisome proliferation due to trichloroethylene: A biochemical human hazard assessment
95. Hepatic peroxisomal changes induced by a tetrazole-substituted alkoxyacetophenone in rats and comparison with other species
96. Species differences in nafenopin-induced hepatic peroxisome proliferation
97. Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset
98. Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients
99. Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man
100. Stimulation of DNA synthesis but not of peroxisomal β-oxidation by nafenopin in primary cultures of marmoset hepatocytes